German Pharmacies Face Negotiation Challenges After Reform Expansion
The recent reform of pharmacy regulations in Germany has introduced an expanded range of services that pharmacies are now authorized to provide. As part of this legislative update, pharmacies gained approval to offer additional vaccinations, rapid diagnostic tests, and venous blood collection, alongside five new pharmaceutical services. These changes represent a significant shift in the healthcare landscape, aiming to enhance the role and visibility of pharmacies within the broader health system.
The implementation of these new services brings with it a complex set of financial and administrative considerations. While the expansion is intended to increase healthcare access and improve patient outcomes, the financial sustainability of these services remains a critical concern for pharmacy operators. According to pharmacy association representatives, the remuneration offered by statutory health insurance providers has not yet reached levels that would ensure the economic viability of the expanded services, especially for small and medium-sized pharmacy businesses.
Under the new legal framework, the German Pharmacists' Association (Deutscher Apothekerverband, DAV) and the National Association of Statutory Health Insurance Funds (GKV-Spitzenverband) are required to negotiate remuneration rates for the newly authorized services. These negotiations are expected to cover a wide range of topics, including the annual adjustment of fixed and variable compensation components starting in 2028, as well as the fees for administering a broader spectrum of vaccines. An agreement on the pricing for these services is necessary before they can be rolled out nationwide in a financially sustainable manner.
One of the immediate challenges lies in the extension of the vaccination agreement to include all inactivated vaccines, not just those for influenza and COVID-19. The compensation structure for these additional vaccinations must be determined through negotiations between the relevant associations and the statutory health insurance funds. Similarly, changes to the reimbursement system for compounded prescription substances, as stipulated by the Pharmacy Supply Development Act (ApoVWG), require new agreements and adjustments in billing practices.
Further complexity arises from the introduction of pharmaceutical services focused on prevention, risk factor counseling for cardiovascular diseases and diabetes, and ongoing support for patients on long-term medication. The financial terms for these services are still under discussion, with pharmacy stakeholders emphasizing the importance of ensuring that the compensation reflects the operational costs and the value of professional expertise provided by pharmacists.
Additionally, the reform has implications for the governance and liability structure within the joint arbitration committees responsible for resolving disputes between pharmacies and insurers. The legislation now spreads liability for any imposed sanctions across the entire committee, rather than assigning it to individual members. While this change is intended to support more effective decision-making, its practical impact remains to be seen, given the ongoing concerns about legal and financial risks for committee members.
The expanded range of pharmacy services introduced by the reform aims to strengthen the healthcare system and improve patient care. However, successful implementation will depend on the outcome of negotiations between pharmacy associations and statutory health insurance providers. Achieving fair and economically viable remuneration for the new services is seen as critical to ensuring their availability across the country and safeguarding the economic stability of local pharmacies.